Bolt Biotherapeutics (BOLT) Current Deferred Revenue (2020 - 2026)
Bolt Biotherapeutics (BOLT) posted Current Deferred Revenue of $630000.0 for Q1 2026, up 40.31% sequentially from $449000.0 in Q4 2025, and down 79.57% YoY from $3.1 million in Q1 2025.
Bolt Biotherapeutics (BOLT) Current Deferred Revenue (2020 - 2026) Analysis & Trends
Bolt Biotherapeutics has reported Current Deferred Revenue for 7 years, with the latest figure at $630000.0 in Q1 2026.
- Quarterly Current Deferred Revenue fell 79.57% year-over-year to $630000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $630000.0 (down 79.57% YoY) and the FY2025 annual result came in at $449000.0, down 85.11% from the prior year.
- Current Deferred Revenue improved to $630000.0 in Q1 2026 per BOLT's latest filing, from $449000.0 in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $3.5 million in Q2 2022 and troughed at $449000.0 in Q4 2025.
- A 5-year average of $2.2 million and a median of $2.0 million in 2024 frame the typical range for Current Deferred Revenue.
- The sharpest annual moves came in 2022 and 2025: Current Deferred Revenue jumped 129.56% in 2022, then plunged 85.11% in 2025.
- Over 5 years, Current Deferred Revenue stood at $2.0 million in 2022, then increased by 10.44% to $2.2 million in 2023, then surged by 36.98% to $3.0 million in 2024, then tumbled by 85.11% to $449000.0 in 2025, then soared by 40.31% to $630000.0 in 2026.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $630000.0, $449000.0, and $1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Bolt Biotherapeutics | 5.48 Mn | 5.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 819,000.00 |
| Mar 31, 2026 | 630,000.00 |
| Dec 31, 2025 | 449,000.00 |
| Sep 30, 2025 | 1.91 Mn |
| Jun 30, 2025 | 2.51 Mn |
| Mar 31, 2025 | 3.08 Mn |
| Dec 31, 2024 | 3.02 Mn |
| Sep 30, 2024 | 1.97 Mn |
| Jun 30, 2024 | 2.02 Mn |
| Mar 31, 2024 | 2.50 Mn |
| Dec 31, 2023 | 2.20 Mn |
| Sep 30, 2023 | 1.94 Mn |
| Jun 30, 2023 | 1.69 Mn |
| Mar 31, 2023 | 1.60 Mn |
| Dec 31, 2022 | 1.99 Mn |
| Sep 30, 2022 | 3.17 Mn |
| Jun 30, 2022 | 3.51 Mn |
| Mar 31, 2022 | 3.45 Mn |
| Dec 31, 2021 | 2.87 Mn |
| Sep 30, 2021 | 5.21 Mn |